Cefaleia por compressão externa durante a pandemia de Covid-19: uma entidade negligenciada
DOI:
https://doi.org/10.48208/HeadacheMed.2023.16Palavras-chave:
Cefaleia, Covid-19, Máscara n95, Proteção para o rosto, Óculos de proteção, Equipamento de proteção individualResumo
Introdução
Os Equipamentos de Proteção Individual (EPI) fazem parte da rotina de trabalho dos profissionais de saúde, principalmente durante as pandemias. Durante a pandemia de Covid-19, o uso de EPI tornou-se constante por longas jornadas de trabalho, resultando em efeitos adversos à saúde dos profissionais, principalmente cefaleia.
Objetivo
Nesta revisão, exploramos a literatura científica sobre a cefaleia associada ao uso prolongado de EPI durante a pandemia de coronavírus.
Método
Trata-se de uma revisão narrativa da literatura realizada nas bases de dados PubMed e Web of Science de acordo com os seguintes descritores MeSH: “Face shield”, “Headache” e “Covid-19”. Foram incluídos artigos que analisaram a presença de cefaleia e outros eventos adversos em profissionais de saúde sob uso prolongado de EPI.
Resultados
Os estudos incluídos apontam a cefaleia como o evento adverso mais prevalente, tanto o surgimento de uma nova cefaleia quanto o agravamento de uma cefaleia anterior. Outros efeitos também foram encontrados, como marcas de pressão na pele, hiperemia nas áreas de contato; sufocamento; concentração reduzida e sudorese excessiva.
Conclusão
O uso de EPI por longos períodos pode causar dores de cabeça por compressão externa, além de outros eventos indesejados. Esses efeitos revelam a importância de estudos para tornar o EPI mais eficiente, garantindo proteção ao indivíduo sem causar desconforto.
Downloads
Referências
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38(1): 1-211 Doi:10.1177/0333102417738202 DOI: https://doi.org/10.1177/0333102417738202
Harris L, L’Italien G, Kumar A, Seelam P, LaVallee C, Coric V and Lipton RB. Real‐world assessment of the relationship between migraine‐related disability and healthcare costs in the United States. Headache: The Journal of Head and Face Pain 2022; 62(4): 473-481 Doi:10.1111/head.14289 DOI: https://doi.org/10.1111/head.14289
Schwedt TJ, Chiang C-C, Chong CD and Dodick DW. Functional MRI of migraine. The Lancet Neurology 2015; 14(1): 81-91 Doi:10.1016/s1474-4422(14)70193-0 DOI: https://doi.org/10.1016/S1474-4422(14)70193-0
Hovaguimian A and Roth J. Management of chronic migraine. Bmj 2022; Doi:10.1136/bmj-2021-067670 DOI: https://doi.org/10.1136/bmj-2021-067670
Lin Y-K, Tsai C-L, Lin G-Y, Chou C-H and Yang F-C. Pathophysiology of Chronic Migraine: Insights from Recent Neuroimaging Research. Current Pain and Headache Reports 2022; 26(11): 843-854 Doi:10.1007/s11916-022-01087-x DOI: https://doi.org/10.1007/s11916-022-01087-x
Oh SY, Kang JJ, Park HK, Cho SJ, Hong Y, Moon HS, . . . Chu MK. Clinical characteristics of medication‐overuse headache according to the class of acute medication: A cross‐sectional multicenter study. Headache: The Journal of Head and Face Pain 2022; 62(7): 890-902 Doi:10.1111/head.14363 DOI: https://doi.org/10.1111/head.14363
Krymchantowski AV, Jevoux CC, Krymchantowski AG, Vivas RS and Silva-Néto R. Medication overuse headache: an overview of clinical aspects, mechanisms, and treatments. Expert Review of Neurotherapeutics 2020; 20(6): 591-600 Doi:10.1080/14737175.2020.1770084 DOI: https://doi.org/10.1080/14737175.2020.1770084
Manack A, Buse DC, Serrano D, Turkel CC and Lipton RB. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology 2011; 76(8): 711-718 Doi:10.1212/WNL.0b013e31820d8af2 DOI: https://doi.org/10.1212/WNL.0b013e31820d8af2
Krymchantowski A, Jevoux C and Valença M. Medication-Overuse Headache: Differences between Daily and Near-Daily Headache Patients. Brain Sciences 2016; 6(3): Doi:10.3390/brainsci6030030 DOI: https://doi.org/10.3390/brainsci6030030
Diener H-C, Kropp P, Dresler T, Evers S, Förderreuther S, Gaul C, . . . Lampl C. Management of medication overuse (MO) and medication overuse headache (MOH) S1 guideline. Neurological Research and Practice 2022; 4(1): Doi:10.1186/s42466-022-00200-0 DOI: https://doi.org/10.1186/s42466-022-00200-0
Find NL, Terlizzi R, Munksgaard SB, Bendtsen L, Tassorelli C, Nappi G, . . . Jensen R. Medication overuse headache in Europe and Latin America: general demographic and clinical characteristics, referral pathways and national distribution of painkillers in a descriptive, multinational, multicenter study. The Journal of Headache and Pain 2016; 17(1): Doi:10.1186/s10194-016-0612-2 DOI: https://doi.org/10.1186/s10194-016-0612-2
Lisicki M, Flores JAC, Bordini CA, Goicochea MT and Peres MFP. Bridging the gaps of headache care for underserved populations: A medication overuse headache survey among international headache society members from Latin America. Cephalalgia Reports 2019; 2(Doi:10.1177/2515816318824076 DOI: https://doi.org/10.1177/2515816318824076
Viana M, De Icco R, Allena M, Sances G, Højland JR, Katsarava Z, . . . Stoppini A. Clinical Subtypes of Medication Overuse Headache – Findings From a Large Cohort. Headache: The Journal of Head and Face Pain 2019; 59(9): 1481-1491 Doi:10.1111/head.13641 DOI: https://doi.org/10.1111/head.13641
Diener HC, Antonaci F, Braschinsky M, Evers S, Jensen R, Lainez M, . . . Petersen JA. European Academy of Neurology guideline on the management of medication‐overuse headache. European Journal of Neurology 2020; 27(7): 1102-1116 Doi:10.1111/ene.14268 DOI: https://doi.org/10.1111/ene.14268
Lake AE. Medication Overuse Headache: Biobehavioral Issues and Solutions. Headache: The Journal of Head and Face Pain 2006; 46(s3): S88-S97 Doi:10.1111/j.1526-4610.2006.00560.x DOI: https://doi.org/10.1111/j.1526-4610.2006.00560.x
Scher AI and Bendtsen L. Patient-Centered Treatment of Chronic Migraine With Medication Overuse. Neurology 2022; 98(14): 563-564 Doi:10.1212/wnl.0000000000200252 DOI: https://doi.org/10.1212/WNL.0000000000200252
Saper JR, Hamel RL and Lake AE. Medication Overuse Headache (MOH) is a Biobehavioural Disorder. Cephalalgia 2016; 25(7): 545-546 Doi:10.1111/j.1468-2982.2005.00879.x DOI: https://doi.org/10.1111/j.1468-2982.2005.00879.x
Carlsen LN, Westergaard ML, Bisgaard M, Schytz JB and Jensen RH. National awareness campaign to prevent medication-overuse headache in Denmark. Cephalalgia 2017; 38(7): 1316-1325 Doi:10.1177/0333102417736898 DOI: https://doi.org/10.1177/0333102417736898
Santiago MDS, Carvalho DdS, Gabbai AA, Pinto MMP, Moutran ARC and Villa TR. Amitriptyline and aerobic exercise or amitriptyline alone in the treatment of chronic migraine: a randomized comparative study. Arquivos de Neuro-Psiquiatria 2014; 72(11): 851-855 Doi:10.1590/0004-282x20140148 DOI: https://doi.org/10.1590/0004-282X20140148
Tassorelli C, Jensen R, Allena M, De Icco R, Sances G, Katsarava Z, . . . Nappi G. A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study. Cephalalgia 2014; 34(9): 645-655 Doi:10.1177/0333102414521508 DOI: https://doi.org/10.1177/0333102414521508
Sun-Edelstein C and Rapoport AM. Update on the Pharmacological Treatment of Chronic Migraine. Current Pain and Headache Reports 2016; 20(1): Doi:10.1007/s11916-015-0533-9 DOI: https://doi.org/10.1007/s11916-015-0533-9
Kowacs F, Roesler CAdP, Piovesan ÉJ, Sarmento EM, Campos HCd, Maciel Jr JA, . . . Jurno ME. Consensus of the Brazilian Headache Society on the treatment of chronic migraine. Arquivos de Neuro-Psiquiatria 2019; 77(7): 509-520 Doi:10.1590/0004-282x20190078 DOI: https://doi.org/10.1590/0004-282x20190078
Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, . . . Brin MF. OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program. Headache: The Journal of Head and Face Pain 2010; 50(6): 921-936 Doi:10.1111/j.1526-4610.2010.01678.x DOI: https://doi.org/10.1111/j.1526-4610.2010.01678.x
Sandrini G, Perrotta A, Tassorelli C, Torelli P, Brighina F, Sances G and Nappi G. Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. The Journal of Headache and Pain 2011; 12(4): 427-433 Doi:10.1007/s10194-011-0339-z DOI: https://doi.org/10.1007/s10194-011-0339-z
Raffaelli B and Reuter U. The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy. Neurotherapeutics 2018; 15(2): 324-335 Doi:10.1007/s13311-018-0622-7 DOI: https://doi.org/10.1007/s13311-018-0622-7
Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, . . . Cady R. Efficacy and safety of eptinezumab in patients with chronic migraine. Neurology 2020; 94(13): e1365-e1377 Doi:10.1212/wnl.0000000000009169 DOI: https://doi.org/10.1212/WNL.0000000000009169
Lipton RB and Silberstein SD. Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention. Headache: The Journal of Head and Face Pain 2015; 55(103-122 Doi:10.1111/head.12505_2 DOI: https://doi.org/10.1111/head.12505_2
Agostoni EC, Barbanti P, Calabresi P, Colombo B, Cortelli P, Frediani F, . . . Russo A. Current and emerging evidence-based treatment options in chronic migraine: a narrative review. The Journal of Headache and Pain 2019; 20(1): Doi:10.1186/s10194-019-1038-4 DOI: https://doi.org/10.1186/s10194-019-1038-4
Diener H-C, Dodick DW, Goadsby PJ, Lipton RB, Olesen J and Silberstein SD. Chronic migraine—classification, characteristics and treatment. Nature Reviews Neurology 2012; 8(3): 162-171 Doi:10.1038/nrneurol.2012.13 DOI: https://doi.org/10.1038/nrneurol.2012.13
Krymchantowski AV, Krymchantowski AGF and Jevoux CdC. Medication-overuse headache. Retrospective comparison of preventive treatments. Arquivos de Neuro-Psiquiatria 2018; 76(10): 668-673 Doi:10.1590/0004-282x20180097 DOI: https://doi.org/10.1590/0004-282x20180097
Krymchantowski AV, Tepper SJ, Jevoux C and Valença M. Medication-Overuse Headache: Protocols and Outcomes in 149 Consecutive Patients in a Tertiary Brazilian Headache Center. Headache: The Journal of Head and Face Pain 2017; 57(1): 87-96 Doi:10.1111/head.12970 DOI: https://doi.org/10.1111/head.12970
Dozza ALCB and Krymchantowski AV. Adherence to migraine treatment does not depend on the number of prescribed medications. Arquivos de Neuro-Psiquiatria 2013; 71(3): 171-173 Doi:10.1590/s0004-282x2013000300008 DOI: https://doi.org/10.1590/S0004-282X2013000300008
Krymchantowski AV, da Cunha Jevoux C and Bigal ME. Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders. The Journal of Headache and Pain 2011; 13(1): 53-59 Doi:10.1007/s10194-011-0395-4 DOI: https://doi.org/10.1007/s10194-011-0395-4
Krymchantowski AV and Bigal ME. Polytherapy in the preventive and acute treatment of migraine: fundamentals for changing the approach. Expert Review of Neurotherapeutics 2014; 6(3): 283-289 Doi:10.1586/14737175.6.3.283 DOI: https://doi.org/10.1586/14737175.6.3.283
Krymchantowski AV. Combining therapies for the treatment of migraine: is there a role? Expert Review of Neurotherapeutics 2014; 5(2): 145-147 Doi:10.1586/14737175.5.2.145 DOI: https://doi.org/10.1586/14737175.5.2.145
Ashina M, Terwindt GM, Al-Karagholi MA-M, de Boer I, Lee MJ, Hay DL, . . . Goadsby PJ. Migraine: disease characterisation, biomarkers, and precision medicine. The Lancet 2021; 397(10283): 1496-1504 Doi:10.1016/s0140-6736(20)32162-0 DOI: https://doi.org/10.1016/S0140-6736(20)32162-0
Pellesi L, Do TP, Ashina H, Ashina M and Burstein R. Dual Therapy With Anti‐CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale? Headache: The Journal of Head and Face Pain 2020; 60(6): 1056-1065 Doi:10.1111/head.13843 DOI: https://doi.org/10.1111/head.13843
Negro A, Curto M, Lionetto L and Martelletti P. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. The Journal of Headache and Pain 2016; 17(1): Doi:10.1186/s10194-016-0591-3 DOI: https://doi.org/10.1186/s10194-016-0591-3
Pensato U, Baraldi C, Favoni V, Mascarella D, Matteo E, Andrini G, . . . Cevoli S. Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache. Cephalalgia 2022; 42(7): 645-653 Doi:10.1177/03331024211067791 DOI: https://doi.org/10.1177/03331024211067791
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2023 Erlene Roberta Ribeiro dos Santos, Amos Lal, Felipe Maia Tardieux, Elayne Cristina de Oliveira Ribeiro, Henry Martins Soares Fortes, Marcelo Moraes Valença (Author)
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
